The largest North American automotive services franchisor — Take 5 Oil Change, Meineke, Maaco, CARSTAR, Auto Glass Now. On February 23 2026 the Audit Committee concluded material errors in FY2023, FY2024, all 2024 quarters, and Q1–Q3 2025 — a three-year restatement. Sixty days later, management still has not disclosed what was wrong.

What the filing says

The April 21 8-K confirmed DRVN will miss its April 26 FY2025 10-K deadline (Nasdaq Rule 5250(c)(1) deficiency). Items 2.02 preliminary results, 3.01 Nasdaq deficiency, 7.01 Reg FD. The restated periods span three years — ≈2x the Audit Analytics Big R average of 1.60 years. Nature of errors not disclosed as of April 22.

One detail from the prior filing record matters here. On March 11 DRVN executed ABS Base Indenture Amendment No. 1, modifying GAAP compliance definitions and adding a 90-day post-restatement grace period for covenant mechanics. Section 4.1(i)(ii) — the 10-K delivery obligation to trustee Citibank — was left at April 26, unamended. Management had five weeks between that amendment and April 26; Section 4.1(i)(ii) was not amended in that window. The deadline is now missed. No waiver from Control Party Midland Loan Services (PNC) has been publicly disclosed. $1.6B in Class A-2 notes sit on an uncured non-payment technical condition.

The SMCI template (Aug 2024 – Feb 2025) is instructive. SMCI's auditor resigned fast; the nature of the errors was diagnosable within weeks (inventory adjustments); the 10-K filed within Nasdaq's window. DRVN is the inverse: auditor (Grant Thornton) still in place, nature silent at 60 days, scope 2x larger. Neither sequence is reassuring, but DRVN's is the slower one.

Operations look OK: Take 5 SSS +4.3–4.5% (Q1 2026, preliminary), FY2025 EBITDA $440–450M, $500M net debt reduction in one quarter from car wash divestitures (US to Whistle Express $385M, International to Franchise Equity Partners ~€411M). Revolvers undrawn, $130M cash.

What the market thinks

Stock $13 vs analyst mean target ≈$19. Options P/C 0.17 — retail is buying calls. Short interest 22% / 5.1 DTC — informed shorts disagree. The price-implied split between bounded and adverse outcomes is not cleanly solvable from one anchor; what we can observe is that short interest and put-skew are consistent with ≈25–35% weight on adverse resolution, and call flow is consistent with retail pricing <15% tail risk.

Our factor view on the nature-of-errors disclosure (CATALYST, 90d horizon, 60d half-life): 55% bounded / 25% franchise-accounting / 20% systemic. The delta against the options-implied tail is roughly 10–15pp on adverse-outcome probability — smaller than the informed-short crowd suggests, larger than the retail call structure prices. The gap is between informed positioning and retail option flow; we sit closer to the shorts.

Why the gap exists

The March 11 amendment language is in an exhibit, not a press release. Section 4.1(i)(ii) is not referenced in any sell-side note we can find. Retail call flow prices the visible restatement (late 10-K) without pricing the $1.6B contingent liability buried in the exhibit stack.

Peer comparison sharpens the idiosyncrasy. Five public WBS franchisors (WEN, JACK, WING, DPZ, PLNT) filed FY2025 10-Ks on time; zero restatements, zero amendments. DPZ and PLNT issued fresh A-2 notes in 2H 2025 — the WBS capital market is healthy. DRVN itself refinanced $500M at BBB/BBB- in October 2025, five months before Feb 23; the rating agencies missed it too. This is DRVN-specific.

What the $17 → $13 repricing already captures: "late filing and restatement exist." What it does not obviously capture: the specific uncured Section 4.1(i)(ii) condition, the base-rate implication of a 3-year silent-nature scope, and the absence of a public waiver. Those are the three observations doing the incremental work.

Risks (ranked)

1. Bounded disclosure + clean ABS waiver. Stock rerates to $15–17. ≈40% probability. Primary risk for any bearish expression.
2. Squeeze tail. 22% SI / 5.1 DTC. Any "we filed" headline spikes the equity. The reason equity short is the wrong instrument.
3. Take-private bid. LGP just took MCW at $7 / $3.1B / 29% premium. Restatement depresses public mark; sponsor arithmetic works. ≈15%. Activist absence on a 22% SI name with this comp is noticeable — bears watching in 13D filings.
4. Take 5 share loss. Running 130–150bps below VVV SSS for multiple quarters cuts both ways: category healthy (bullish floor) but Take 5 specifically losing share (bearish trend). Our F5 "holds" probability at 60% could be closer to 45–50%.

Catalysts

What would change our mind

• Item 4.01 ruling out auditor departure: raises P(bounded) toward 70%; thesis weakens.
• ABS 8-K disclosing Midland waiver on Section 4.1(i)(ii): the technical condition resolves.
• Nature of errors disclosed as discontinued-ops / segment reclassification: thesis collapses toward neutral.
• A-2 note spreads trading in line with DPZ/PLNT comparable A-2 (credit market endorsing the "contained" read): confirms retail call pricing, weakens thesis.
• VVV Q2 SSS decelerating <3%: weakens the operating floor — supports the bear, not against.

Expression (conditional on verification)

The equity is a crowded short — 22% SI / 5.1 DTC — with meaningful gap-up exposure on any "we filed" headline. A-2 note credit spread widening is the cleanest expression of the thesis, though access is limited to institutional participants. July $10 puts would capture the correlated bear scenario (bounded failure + auditor resignation + ABS amendment) without squeeze exposure. EV is highly IV-dependent: approximately +30% at 80% IV, approximately +65% at 60% IV. Actual IV must be confirmed before the EV math holds. The favorable print should not be assumed.

Open research gaps

1. DRVN Series 2024-1 / 2025-1 A-2 note trading levels (TRACE/Bloomberg). If spreads have widened materially from comparable WBS A-2, credit market is pricing the thesis; if not, credit market agrees with retail call flow.
2. Grant Thornton audit fee trend from last DEF 14A vs current. Rising = scope expanding.
3. O'Melia Jan 21 Form 4 transaction code from EDGAR primary source (P/S/F/M). Unverified via secondary data; not cited here.
4. VVV and MNRO Q2 earnings call commentary on DRVN weakness — silence is itself signal.
5. 13D/13G filings for activist accumulation given 22% SI and MCW take-private comp.

Evidence